{"result": "(\"entity\"<|>CRH HUMANO<|>ORGANIZATION<|>CRH humano is a human corticotropin-releasing hormone used in Europe for medical treatments, particularly in relation to growth hormone issues.)\n##\n(\"entity\"<|>TUMORES CARCINOIDES<|>EVENT<|>Tumores carcinoides are a type of neuroendocrine tumor that can exhibit similar responses to pituitary tumors producing ACTH, relevant in the context of growth hormone treatment.)\n##\n(\"entity\"<|>ACTH<|>EVENT<|>ACTH, or adrenocorticotropic hormone, is a hormone produced by the pituitary gland that stimulates the adrenal glands, relevant in the context of growth hormone treatment.)\n##\n(\"entity\"<|>GH RECOMBINANTE<|>EVENT<|>GH recombinante refers to recombinant growth hormone, a synthetic form of growth hormone used in medical treatments.)\n##\n(\"entity\"<|>DIABETES<|>EVENT<|>Diabetes is a chronic condition that affects how the body processes blood sugar (glucose), mentioned in the context of potential risks associated with growth hormone treatment.)\n##\n(\"entity\"<|>EPIFISIÓN FEMORAL<|>EVENT<|>Epifisiólisis femoral is a condition related to the growth plate of the femur, mentioned as a potential risk associated with growth hormone treatment.)\n##\n(\"entity\"<|>INSULIN<|>EVENT<|>Insulin is a hormone that regulates blood sugar levels, mentioned in the context of testing for growth hormone deficiency.)\n##\n(\"entity\"<|>TALLA BAJA<|>EVENT<|>Talla baja refers to short stature, a condition that may prompt evaluation for growth hormone deficiency.)\n##\n(\"entity\"<|>VELOCIDAD DE CRECIMIENTO<|>EVENT<|>Velocidad de crecimiento refers to growth rate, an important measure in assessing growth hormone deficiency.)\n##\n(\"relationship\"<|>CRH HUMANO<|>GH RECOMBINANTE<|>CRH humano is used in treatments that may involve GH recombinante, particularly in Europe<|>5)\n##\n(\"relationship\"<|>TUMORES CARCINOIDES<|>ACTH<|>Tumores carcinoides can produce ACTH, similar to pituitary tumors, which is relevant in the context of growth hormone treatment<|>6)\n##\n(\"relationship\"<|>GH RECOMBINANTE<|>DIABETES<|>GH recombinante treatment may increase the risk of diabetes, as mentioned in the context of adverse events<|>4)\n##\n(\"relationship\"<|>GH RECOMBINANTE<|>EPIFISIÓN FEMORAL<|>GH recombinante treatment may lead to epifisiólisis femoral, as mentioned in the context of adverse events<|>4)\n##\n(\"relationship\"<|>INSULIN<|>GH RECOMBINANTE<|>Insulin testing is relevant for evaluating growth hormone deficiency, particularly in the context of GH treatment<|>5)\n##\n(\"relationship\"<|>TALLA BAJA<|>GH RECOMBINANTE<|>Talla baja is a condition that may lead to the evaluation and treatment with GH recombinante<|>7)\n##\n(\"relationship\"<|>VELOCIDAD DE CRECIMIENTO<|>GH RECOMBINANTE<|>Velocidad de crecimiento is a critical measure in assessing the need for GH recombinante treatment<|>7)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: al 50%, independientemente de que se trate de micro- o macroadenomas.                                                                        elevados de GH con IGF-1 muy baja. El tratamiento se realizaría con IGF-1 puesto que la\n           Esto quizá se pueda relacionar con el uso en Europa de CRH humano, menos potente que                                                                          alteración del receptor hace que la GH recombinante sea ineficaz (respuesta A).\n           el ovino, con el que se han realizado los principales estudios.                                                                                               Una vez instaurado el tratamiento con GH, la monitorización se realiza con criterios auxo-\n        •  Se han descrito algunos casos de tumores carcinoides con respuesta similar a la de                                                                            lógicos de talla y velocidad de crecimiento. La determinación seriada de IGF-1 se requiere\n           los tumores hipofisarios productores de ACTH, puesto que sus células tienen receptores                                                                        para valorar la seguridad y el grado de cumplimiento y no debe sobrepasar los rangos de\n           para CRH. Por tanto, en casos en los que la clínica o los datos bioquímicos sugieran un                                                                       normalidad, aunque no siempre concuerda con los datos auxológicos (respuesta C).\n           origen ectópico puede ser necesario aumentar el punto de corte y exigir elevaciones de                                                                        Los eventos adversos más frecuentes con la GH recombinante son: artralgias, edema, gi-\n           ACTH cercanas al 100% en respuesta a la CRH para poder aumentar el valor predictivo                                                                           necomastia o más raramente hipertensión intracraneal benigna. Puede haber aumento del\n           positivo (y descartar de forma fiable la producción ectópica de ACTH).                                                                                        número, tamaño y pigmentación de los nevus (sin aumento de melanoma) y cierto riesgo\n        Referencias:                                                                                                                                                     aumentado de diabetes (no de hipoglucemia, respuesta D) y de epifisiólisis femoral.\n        • Álvarez San Martín RM, Urioste Fondo A, Vidal Casariego A. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad                                   Referencias:\n          Española de Endocrinología y Nutrición; 2015. Capítulo 47. Pruebas funcionales en endocrinología; [citado 29 abril 2019]. Disponible                           • Peinó R. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de Endocrinología y Nutrición; 2015. Capítulo\n          en: https://manual.seen.es/article?id=554c74e1-da58-49fc-a805-5173ac18103c                                                                                       18. Deficiencia de hormona del crecimiento en el niño y en el adulto; [citado 29 de abril de 2019]. Disponible en: https://manual.seen.\n        • Estrada J, Abad A, Aller J. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española de Endocrinología y Nutrición; 2015. Capítulo             es/article?id=55114bc0-fb68-4bc1-87c3-2bcdac18103c\n          33. Síndrome de Cushing; [citado 29 de abril de 2019]. Disponible en: https://manual.seen.es/article?id=55114c66-816c-4250-91fe-2bcdac18103c\n\n\n\n52                                                                                                                                                                                                                                                                                                  53\n---\n                                                                                                                                                                                                                                           HIPÓFISIS                        1\n\n\n\n    43  Respecto al déficit de GH en la época de transición desde la infancia/adolescencia                                                         44  ¿En cuál de las siguientes circunstancias debe realizarse de forma inmediata un\n        a la edad adulta señale la afirmación incorrecta:                                                                                              estudio para evaluar la presencia de un déficit de GH en la infancia?\n        A. Los pacientes con déficit aislado idiopático de GH en la infancia deben reevaluarse                                                         A. Talla baja inferior a 3 DE de la media en la población de referencia.\n            mediante un test de estímulo para GH tras al menos un mes sin tratamiento.                                                                 B. Talla inferior a 1,5 DE de la talla media parental.\n        B. Durante la transición, el punto de corte de GH tras estímulo, por debajo del cual se                                                        C. Velocidad de crecimiento inferior a 2 DE respecto a la media de la población\n            confirma el déficit, debe ser 5,1 g/l tras hipoglucemia insulínica.                                                                            de referencia durante un año.\n        C. La dosis de reinicio de somatotropina humana recombinante durante la transición                                                             D.  Todas las respuestas son correctas.\n            debe ser entre 0,6 y 1 mg diarios.\n        D.  El objetivo del tratamiento es mantener la concentración de IGF-1 en la zona media                                                         COMENTARIO\n            del rango normal para la edad del paciente.\n                                                                                                                                                       Los criterios auxológicos y clínicos para iniciar un estudio y descartar déficit de GH son:\n        COMENTARIO                                                                                                                                       •  Talla inferior a <3 DE de la media en la población de referencia.\n        El período de transición es un\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>ORGANIZATION<|>The Sociedad Española de Endocrinología y Nutrición is a Spanish organization focused on endocrinology and nutrition, providing guidelines and manuals for medical professionals.)\n##\n(\"entity\"<|>ÁLVAREZ SAN MARTÍN RM<|>PERSON<|>Álvarez San Martín RM is an author of a manual on endocrinology and nutrition, contributing to the field with research and guidelines.)\n##\n(\"entity\"<|>URIOSTE FONDO A<|>PERSON<|>Urioste Fondo A is an author of a manual on endocrinology and nutrition, contributing to the field with research and guidelines.)\n##\n(\"entity\"<|>VIDAL CASARIEGO A<|>PERSON<|>Vidal Casariego A is an author of a manual on endocrinology and nutrition, contributing to the field with research and guidelines.)\n##\n(\"entity\"<|>MADRID<|>GEO<|>Madrid is the capital city of Spain, where the Sociedad Española de Endocrinología y Nutrición is based.)\n##\n(\"entity\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>EVENT<|>The Manual de Endocrinología y Nutrición is a comprehensive guide published by the Sociedad Española de Endocrinología y Nutrición, detailing various aspects of endocrinology and nutrition.)\n##\n(\"relationship\"<|>ÁLVAREZ SAN MARTÍN RM<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Álvarez San Martín RM is one of the authors of the Manual de Endocrinología y Nutrición, contributing to its content<|>8)\n##\n(\"relationship\"<|>URIOSTE FONDO A<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Urioste Fondo A is one of the authors of the Manual de Endocrinología y Nutrición, contributing to its content<|>8)\n##\n(\"relationship\"<|>VIDAL CASARIEGO A<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Vidal Casariego A is one of the authors of the Manual de Endocrinología y Nutrición, contributing to its content<|>8)\n##\n(\"relationship\"<|>MADRID<|>SOCIEDAD ESPAÑOLA DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>The Sociedad Española de Endocrinología y Nutrición is located in Madrid, the capital of Spain<|>7)\n<|COMPLETE|>"}]}